- MEP Lola Sánchez questions the European Commission: EU's position on the UN High-Level Panel on Access to Medicines at WIPO
- WTO TRIPS Council: Brazilian submission on Ecommerce and Copyright
- All 12 Zhang/Broad Institute CRISPR patents declare US funding and rights in inventions
- KEI Comments filed in USTR Special 301 Review
- WTO Trade Policy Review: Members question the United States on compulsory licensing, Bayh-Dole, UNHLP & Section 337
- EB140: WHO adopts decision on terms of reference for overall programme review of the GSPOA (31 Jan 2017)
- EB140 heats up during discussions of proposed changes to resolution on TOR of Overall Programme Review of GSPOA
- Feb 24, 2017 - U.S. History, Experiences, and Prospects of Compulsory Licensing of Medical Patents
- Chilean Cámara de Diputados votes overwhelmingly to advance compulsory licensing of drug patents.
- EB140: Statement of India on the Report of the United Nations High-Level Panel on Access to Medicines
SCOTUS Oral Arguments in Bowman v. Monsanto; Court to Decide Application of Patent Exhaustion to Self-Replicating TechnologySubmitted by Krista Cox on 19. February 2013 - 14:34
On Tuesday, 19 February 2013, the Supreme Court of the United States heard oral arguments in the case, Bowman v. Monsanto. This case involves the application of the patent exhaustion doctrine to self-replicating technology, in this case, seeds.
MEP Keller questions EU on its position on extension of WTO TRIPS Agreement transition period for Least Developed CountriesSubmitted by thiru on 19. February 2013 - 11:40
On 28 January 2013, the following question tabled by MEP Franziska Keller (Verts/ALE) to the European Union on the EU's position on extension of WTO TRIPS Agreement transition period for Least Developed Countries was made available.
WIPO provides limited access to observe informal negotiations, but bans use of Internet social mediaSubmitted by James Love on 19. February 2013 - 4:09
The WIPO Special Session negotiating the text of a new treaty on copyright exceptions for persons with disabilities is meeting from February 18 to 22. Yesterday all of the negotiations were behind closed doors, but this morning WIPO made public a copy of the revised negotiating text (available here: http://www.keionline.org/node/1651).
Attached below is the version of the negotiating text from February 18. It includes several new or edited footnotes.
Fn5. concerns language on translation.
Fns 6 and 9 are proposals for language that would permit a country to limit exceptions to cases where "the particular accessible format, cannot be obtained commercially under reasonable terms for beneficiary persons in that [Member State’s] market."
Fns 7 and 8 are proposals to address the delivery of an accessible work to a person in another country. These are among the more contentiousness issues this week.
As mentioned in a previous piece, the trilateral report by the secretariats of the World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the World Trade Organization (WTO), Promoting Access to Medical Technologies and Innovation: Intersections between public health, intellectual property and trade, covers a lot of ground including but not limited to: 1) the global burden of disease and global health risks, 2) health and human rights, 3) access to essential medicines: an indicator for the fulfillment of the right to
On Friday, 8 February 2013, KEI filed comments to USTR on the 2013 Special 301 Review. The comments request support for an extension of the transition period for least-developed countries, issues regarding compulsory licenses, patent linkage, exclusive rights over test data, and standards of patentability. With regard to copyright, KEI submitted comments covering issues of technological protection measures and DMCA-style legislation on notice-and-takedown procedures. KEI also made comments regarding the enforcement of intellectual property rights.
On 13 April 2011, Senator Orrin Hatch (Republican-Utah) wrote a letter to then-Secretary of State, Hillary Clinton complaining about Global Fund's policy on generic procurement and compulsory licensing. With respect to procurement, Sen. Hatch asserted that Global Fund monies were used to procure generic drugs "at unnecessary costs in recipient countries" while branded drugs (all Abbott products) were were available at a lower cost.
Some key events in the early development of the proposal for a Pan African Intellectual Property Organization
10 February 2013
WHO/WIPO/WTO report on Promoting Access to Medical Technologies and Innovation: Article 39.3 and the cost-sharing approachSubmitted by thiru on 6. February 2013 - 10:41
On Tuesday, 5 February 2013, the Secretariats of the World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the World Trade Organization (WTO) released their joint publication, Promoting Access to Medical Technologies and Innovation: Intersections between public health, intellectual property and trade. This 251-page report covers a lot of ground.
In the words of the secretariats,
Notes on the Blur Banff proposal*
KEI Research Note 2013:1
February 1, 2013
This is a brief note on the Blur/Banff proposal for a system of decentralized decision making and competitive intermediaries to provide money to support recorded music that is freely available. Also discussed are extensions of the competitive intermediary approach to other areas where information goods can be supplied as public goods.
On Thursday, 31 January 2013, KEI filed an amicus brief to the Supreme Court of the United States in the case Association for Molecular Pathology, et. al. v. Myriad Genetics, Inc., et. al. Our full brief is available for download here.
KEI files amicus brief in pay-for-delay case; SCOTUS to resolve circuit split on legality of reverse payment settlementsSubmitted by Krista Cox on 28. January 2013 - 15:39
On Monday, 28 January 2013, KEI filed an amicus brief to the Supreme Court of the United States in the case Federal Trade Commission v. Watson Pharmaceuticals**. The case involves a question of whether pay-for-delay settlement agreements, also known as reverse payments (where a branded pharmaceutical company will pay a generic firm to stay off the market for a certain period of time), are per se legal or whether they are presumptively anticompetitive.
WHO Director-General Chan throws down the gauntlet on the CEWG process: "Let's fight this out at the Assembly!"Submitted by thiru on 26. January 2013 - 6:38
* The author thanks Belinda Townsend, Katy Athersuch, Judit Rius Sanjuan and Alice Fabbri for their comprehensive notes during the WHO Executive Board discussion of the CEWG agenda item.
Joint Letter to the 132nd WHO Executive Board: Follow-up of the report of the CEWG
We are writing to express our deep concern at the lack of ambition and apparent inaction of the WHO and Member States in taking forward the work of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG). This inaction is costing lives.
On Wednesday, January 23rd, 2013, the Department of State will convene a meeting to discuss a proposal by the Hague Conference on Private International Law ("Hague Conference") to developing a new "instrument" on the recognition and enforcement of judgments, including "new jurisdictional filters."